Clin2
NCT07378527Possibly a fitRecruiting

Study of ICP-332 for chronic hives not helped by antihistamines

Chronic Spontaneous Urticaria (CSU)

Treatments studied

Part of Immune system & allergy, Skin clinical trials.

This trial tests an experimental drug called ICP-332 for people with chronic spontaneous urticaria (long-term hives) that is not well controlled by standard antihistamines. The goal is to see if the drug is safe and effective at reducing hives.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2/Phase 3
Enrollment
344 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are between 18 and 75 years old.
  • You have had hives (chronic spontaneous urticaria) for at least 6 months.
  • Your hives are not well controlled by second-generation antihistamines (like Zyrtec, Claritin, Allegra).
  • You are not pregnant or breastfeeding.
  • You have no other skin conditions or medical issues that might interfere.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07166211Recruiting· Phase 2
Study of CM512 injection for chronic hives

This trial tests a new injection (CM512) for people with chronic spontaneous urticaria, also known as chronic hives. If you have had itchy hives for at least 6 weeks despite taking regular antihistamines, this study may help find a new treatment option.

Tianjin, Tianjin Municipality
NCT07766499Not yet recruiting· Phase 2
Study of an experimental pill for chronic hives

This study tests an investigational pill called THB335 for adults whose hives (itchy welts) keep appearing despite taking antihistamines. The goal is to see if this treatment can reduce itching and hives and improve quality of life.

NCT07764003Not yet recruiting· Phase 2
New oral medication for chronic hives that resist antihistamines

This study tests a new oral medication (TLL-018) for people with chronic hives that don't fully go away with standard antihistamines. It aims to see if the drug reduces itching and hives better than placebo.

NCT07684560Not yet recruiting· Phase 1
New oral drug for chronic hives

This trial tests a new oral medication for chronic spontaneous urticaria (chronic hives). It is a placebo-controlled study, meaning some participants will get the new drug and some will get a placebo (a pill with no active ingredient). The goal is to see if the new drug is safe and how well it works, possibly providing a new treatment option for those whose hives are not controlled by current antihistamines.

Beijing, Beijing Municipality
NCT07665996Not yet recruiting· Phase 1/Phase 2
A new daily pill for chronic hives when antihistamines are not enough

This trial tests a new daily pill called TLL-018 (a JAK inhibitor) for people with chronic hives that still cause symptoms despite taking antihistamines. It aims to see how fast it relieves itching and hives.

Chengdu, Sichuan
NCT07557888Not yet recruiting
Adding bacterial lysate to antihistamines for chronic hives

This study tests whether adding a bacterial extract called OM-85 to your usual antihistamine helps control chronic hives better than antihistamines alone. It is an observational study, meaning the treatment is decided by your doctor, not assigned randomly.

Yiwu, Zhejiang

Hear when a new Chronic Spontaneous Urticaria (CSU) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.